Sun Pharma Distributors Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 21-06-2024
- Paid Up Capital ₹ 1.50 M
as on 21-06-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 22.96%
(FY 2022)
- Profit 23.12%
(FY 2022)
- Ebitda 26.75%
(FY 2022)
- Net Worth 81.65%
(FY 2022)
- Total Assets 17.09%
(FY 2022)
About Sun Pharma Distributors
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Rama Bijapurkar, Kalyanasundaram Subramanian, and Rakeshchandra Sinha serve as directors at the Company.
- CIN/LLPIN
U51909MH2019PLC322778
- Company No.
322778
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Mar 2019
- Date of AGM
31 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Sun Pharma Distributors Limited offer?
Sun Pharma Distributors Limited offers a wide range of products and services, including Sexual Wellness Products, Erectile Dysfunction Medicine, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Cardiovascular Drugs & Medication, Kidney Drugs.
Who are the key members and board of directors at Sun Pharma Distributors?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rama Bijapurkar  | Director | 16-Jul-2021 | Current |
| Rakeshchandra Sinha | Director | 19-Mar-2019 | Current |
Kalyanasundaram Subramanian  | Director | 19-Mar-2019 | Current |
Financial Performance and Corporate Structure Insights of Sun Pharma Distributors.
Sun Pharma Distributors Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.96% increase. The company also saw a substantial improvement in profitability, with a 23.12% increase in profit. The company's net worth Soared by an impressive increase of 81.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sun Pharma Distributors?
In 2022, Sun Pharma Distributors had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sun Pharma Laboratories LimitedActive 27 years 11 monthsKalyanasundaram Subramanian and Rakeshchandra Sinha are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sun Pharma Distributors?
Sun Pharma Distributors has a workforce of 19 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Pharma Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Pharma Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
